Global clinical research organisation Quintiles has been named as the Asia Pacific Contract Research Organization of the Year by Frost & Sullivan. It bagged the honours for the fourth time in six years.  

The award was presented to the company at the 2011 Frost & Sullivan Asia Pacific Best Practices Awards ceremony held at Singapore.
 
According to  Anand Tharmaratnam, senior vice president and head of Asia Markets. “Asia is the new frontier for drug development as Western companies seek to develop and register products here, and emerging Asia companies seek new global capabilities.  Quintiles’ expertise and global reach allows us to help both groups capitalize on opportunities to bring new and better medicines to patients in need.  We will continue to invest the region to further entrench the position of Quintiles as the drug developer of choice for global and local registration studies.”

In granting the award, Frost & Sullivan cited Quintiles’ top scores in five key areas which covered customer service; innovation; revenue and revenue growth; market share and market share growth; and growth strategy and implementation excellence.

Neha Koul, Healthcare Research Analyst, Frost & Sullivan Asia Pacific, said: “Quintiles is the clear market leader in the APAC CRO region.  Its multiple growth strategies, investments and client services make it well positioned to continue its growth.”